KBC Group’s Cytokinetics CYTK Stock Holding History

KBC Group’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$265K	Buy	4,027 +557	+16%	+$42.5K	﹤0.01%	927
2026 Q2	$296K	Hold	3,470	–	–	﹤0.01%	913
2026 Q1	$229K	Hold	3,470	–	–	﹤0.01%	935
2025 Q4	$220K	Hold	3,470	–	–	﹤0.01%	887
2025 Q3	$191K	Hold	3,470	–	–	﹤0.01%	923
2025 Q2	$115K	Sell	3,470 -1,903	-35%	-$66.2K	﹤0.01%	1112
2025 Q1	$216K	Buy	5,373 +239	+5%	+$11K	﹤0.01%	1026
2024 Q4	$242K	Buy	5,134 +1,902	+59%	+$98.8K	﹤0.01%	1032
2024 Q3	$171K	Buy	3,232 +851	+36%	+$47.4K	﹤0.01%	999
2024 Q2	$129K	Buy	2,381 +362	+18%	+$21.9K	﹤0.01%	1045
2024 Q1	$142K	Sell	2,019 -327	-14%	-$25.3K	﹤0.01%	968
2023 Q4	$196K	Hold	2,346	–	–	﹤0.01%	848
2023 Q3	$69K	Sell	2,346 -5,080	-68%	-$169K	﹤0.01%	1192
2023 Q2	$242K	Sell	7,426 -427	-5%	-$15.8K	﹤0.01%	885
2023 Q1	$276K	Hold	7,853	–	–	﹤0.01%	886
2022 Q4	$360K	Hold	7,853	–	–	﹤0.01%	809
2022 Q3	$380K	Buy	7,853 +1,374	+21%	+$66.1K	﹤0.01%	811
2022 Q2	$255K	Buy	6,479 +3,794	+141%	+$153K	﹤0.01%	919
2022 Q1	$99K	Buy	+2,685	New	+$95.4K	﹤0.01%	1193

Other funds holding CYTK

Polaris Capital Management Boston, Massachusetts $953M AUM 27.74% 1-Year Est. Return

E. Ohman J:or Asset Management Stockholm, Sweden $4.47B AUM 27.58% 1-Year Est. Return

Pinnacle Associates New York $8.92B AUM 43.91% 1-Year Est. Return

Mirador Capital Partners Pleasanton, California $859M AUM 41.74% 1-Year Est. Return

Mutual of America Capital Management New York $10.1B AUM 33.74% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return

Amalgamated Bank New York $14.3B AUM 35.81% 1-Year Est. Return

Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.56B AUM 41.43% 1-Year Est. Return

Yousif Capital Management Bloomfield Hills, Michigan $8.87B AUM 34.1% 1-Year Est. Return

Moody Aldrich Partners Marblehead, Massachusetts $523M AUM 75.24% 1-Year Est. Return

KBC Group's CYTK Position: Q3 2026 in Review

KBC Group increased its Cytokinetics (CYTK) stake by 16% in Q3 2026, buying an estimated $42.5K and bringing the position to 4,027 shares worth $265K. The position accounts for ﹤0.01% of the portfolio, ranked #927.

KBC Group first reported a position in CYTK in Q1 2022 and has held it in 19 quarters since. The position peaked at $380K in Q3 2022. 108 funds tracked by Wall St. Rank hold CYTK as of Q3 2026.

KBC Group held 4,027 shares of Cytokinetics worth $265K as of Q3 2026.
KBC Group bought 557 Cytokinetics shares in Q3 2026, an estimated $42.5K.
Cytokinetics made up ﹤0.01% of KBC Group's portfolio in Q3 2026, its #927 holding.
KBC Group first reported a position in Cytokinetics in Q1 2022 and has held it in 19 quarters since.
KBC Group's Cytokinetics position peaked at $380K in Q3 2022.
108 funds tracked by Wall St. Rank held Cytokinetics as of Q3 2026.

Based on KBC Group's 13F filing for Q3 2026, filed 22 Oct 2026.